Naylor ML, Yun J, Arnold D. No evidence of disease activity achievement over 4 years of peginterferon beta-1a treatment in newly diagnosed patients with relapsing Multiple Sclerosis: subgroup analyses of ADVANCE/ATTAIN. EAN 2018, poster EPR2116.
Solanezumab bij preklinische ziekte van Alzheimer: fase III-resultaten
okt 2023 | Dementie